Skip to main content
The Markets by Proactive
Go to Proactive Australia

Pharma & Biotech

Prana Biotechnology joins with Takeda to investigate lead drug

Prana recently demonstrated the effectiveness of PBT434 in Parkinson’s disease.

Prana Biotechnology Limited (ASX:PBT, NASDAQ:PRAN) has executed a research collaboration with Takeda Pharmaceuticals International to study Prana’s lead movement disorders compound.

The companies will study the ability of Prana’s investigational movement disorders compound, PBT434, to slow or prevent neurodegeneration of the gastrointestinal system.

One of the important non-motor features of Parkinson’s disease is often the early presentation of severe and disabling impairment of gastrointestinal function.

Parkinson’s disease is characterised by the loss of neurons and their networks in the brain and in the gut.

The cause of neurodegeneration and gastrointestinal dysfunction in Parkinson’s disease is not known, but the protein alpha-synuclein has been hypothesised to be implicated in this process.

PBT434 is the first of a new generation of small molecules from a class of drugs that was specifically designed to block the accumulation and aggregation of alpha-synuclein.

Prana recently demonstrated a significant reduction of alpha-synuclein in various pre-clinical models of Parkinson’s disease by using PBT434.

The new research collaboration will investigate the ability of PBT434 to mitigate gastrointestinal dysfunction including constipation, lowered colon motility and inflammation in mouse models.

Prana is expected to begin human testing of PBT434 in a Phase 1 trial later this year.